US neurologists satisfied with current RRMS therapies: Report
Neurologists in the U.S. are largely satisfied with current treatment options for relapsing-remitting multiple sclerosis (RRMS), but opportunities remain…
Articles by Steve Bryson, PhD
Vitamin D supplement reduces progressive MS disease in rats
Vitamin D reduced the signs of inflammation and nerve damage in a rat model of progressive multiple sclerosis (MS),…
NfL blood test may detect neurodegeneration in youngsters
Neurofilament light chain (NfL) protein levels can be used to assess neurodegeneration in children and adolescents with neurological disease, including…
Tecfidera confirmed safe, effective in Black and Hispanic MS patients
Treatment with Tecfidera (dimethyl fumarate) provides a similar long-term benefit for Black and Hispanic people with multiple sclerosis…
Axoltis teaming with InSilicoTrials on MS candidate NX210c
NX210c, an investigational therapy for multiple sclerosis (MS) and other neurodegenerative diseases from Axoltis Pharma, will have its…
Ancestrally-diverse study of genetics in MS recruiting in the UK
People with multiple sclerosis (MS) living in the U.K. who identified as South Asian reported their first symptoms at…
NfL blood levels may help predict long-term progression of MS: Study
Elevated blood levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with long-term disability progression in…
Mavenclad found comparable to Gilenya in highly active MS
Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS)…
Outcomes better for RRMS patients who start on higher efficacy DMTs
Outcomes are better for people with relapsing-remitting multiple sclerosis (RRMS) initially treated with higher efficacy disease-modifying therapies (DMTs)…
Aubagio shifts immune cell balance in RRMS, study reveals
Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between…
Newly discovered genetic variant tied to faster MS progression
Researchers identified a genetic variant that associated with faster multiple sclerosis (MS) progression and greater brain tissue damage, according…
New disability benefits in Canada may help MS, other patients
The government of Canada soon will provide new income benefits designed to help Canadians living with a disability — including…
Stem cell therapy highly effective in active RRMS: Real-world study
Nearly 80% of adults with highly active relapsing-remitting multiple sclerosis (RRMS) were free of relapses or confirmed disability worsening…
Review: Ocrevus best of 4 antibody therapies for progressive MS
Among four antibody-based therapies for multiple sclerosis (MS), Ocrevus (ocrelizumab) works best to prevent disability progression and other…
GlobeStar, AIP team up to design clinical trials for Project Amethyst
GlobeStar Therapeutics (GSTC) is teaming up with Advanced Innovative Partners (AIP) to design and implement clinical trials of Project Amethyst,…
T-cell changes reflect pregnancy’s protective effects in MS
Changes in the gene activity within immune T-cells explain why women with multiple sclerosis (MS) improve during pregnancy, a…
Fatty acid-derived molecules tied to inflammation, disability in study
Altered blood levels of certain fat molecules implicated in inflammatory responses seem to correlate with disability status and markers of…
MRI method detects myelin repair with over-the-counter antihistamine
The over-the-counter antihistamine clemastine has demonstrated an ability to repair myelin, the protective coating on nerve fibers that’s damaged…
Blood-clotting protein triggers brain inflammation in MS: Study
A blood-clotting protein called fibrin can activate immune cells in the brain and contribute to inflammation and neurodegeneration in…
Myelin defects seen before lesions, inflammatory activity in MS: Study
A detailed examination of nerve tissue isolated from multiple sclerosis (MS) patients showed changes to the myelin sheath…
Periods of oxygen deprivation improve symptoms of MS in mice
A non-invasive treatment called acute intermittent hypoxia, or AIH, involving periods of oxygen deprivation, was found to ease signs and…
MS diagnosis rate constant for 20 years, large UK study shows
The rate of multiple sclerosis (MS) diagnoses have remained relatively constant for almost 20 years in the U.K., according…
Nanocapsules with retinoic acid may treat MS inflammation: Study
Modified nanocapsules containing retinoic acid can suppress inflammation and prompt the growth of cells that produce nerve fibers’ myelin coating,…
Researchers uncover key biological pathway for MS
Interleukin-3 (IL-3), an inflammatory signaling protein, seems to coordinate the recruitment of immune cells from the blood into the brain,…
Omega-3 fatty acid transporter vital for myelin sheath production: Study
A protein called Mfsd2a, which transports molecules that contain omega-3 fatty acids, is essential for regulating cells that make the fatty…
Training of pelvic floor muscles in MS found to help urinary symptoms
Training of the pelvic muscles, provided alongside lifestyle advice via telerehabilitation — tailored exercise instruction delivered via an online…
Mavenclad benefits for MS sustained up to 15 years after last treatment
The benefits of Mavenclad (cladribine) were sustained for up to 15 years after its last treatment course in people…
Octopus mega-trial opens to progressive MS patients in the UK
The world’s first mega-trial is recruiting people in the U.K. with progressive forms of multiple sclerosis (MS) to investigate…
Itaconate, a common metabolite, shows promise in MS mouse model
Itaconate, a metabolite produced during cellular energy production activities, was found to restore the balance of immune T cells and…
Vitamin D receptor defines 2 distinct lines of immune cells: Early study
The body has two distinct lineages of immune cells that can be distinguished by the presence or absence of the…